Northern Trust Corp Adagio Therapeutics, Inc. Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

A detailed history of Northern Trust Corp transactions in Adagio Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 568,377 shares of ADGI stock, worth $1.88 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

568,377

Previous 142,199 299.71%

Holding current value

$1.88 Million

Previous $470,000 300.21%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	N/A	426,178 Added 299.71%	568,377 $1.88 Million
Q2 2024 Aug 14, 2024	BUY	N/A	31,504 Added 28.46%	142,199 $470,000
Q1 2024 May 14, 2024	BUY	N/A	5,654 Added 5.38%	110,695 $366,000
Q4 2023 Feb 13, 2024	SELL	N/A	-1,212 Reduced 1.14%	105,041 $347,000
Q3 2023 Nov 13, 2023	BUY	N/A	620 Added 0.59%	106,253 $351,000
Q2 2023 Aug 11, 2023	SELL	N/A	-319,745 Reduced 75.17%	105,633 $349,000
Q1 2023 May 15, 2023	SELL	N/A	-13,342 Reduced 3.04%	425,378 $1.41 Million
Q4 2022 Feb 13, 2023	BUY	$3.08 - $4.05 $20,959 - $27,560	6,805 Added 1.58%	438,720 $1.45 Million
Q3 2022 Nov 14, 2022	BUY	$2.97 - $4.83 $178,758 - $290,708	60,188 Added 16.19%	431,915 $1.35 Million
Q2 2022 Aug 12, 2022	SELL	$2.54 - $4.52 $143,337 - $255,072	-56,432 Reduced 13.18%	371,727 $1.22 Million
Q1 2022 May 13, 2022	BUY	$3.81 - $10.77 $923,300 - $2.61 Million	242,336 Added 130.41%	428,159 $1.95 Million
Q4 2021 Feb 08, 2022	SELL	$6.35 - $47.04 $1,701 - $12,606	-268 Reduced 0.14%	185,823 $1.35 Million
Q3 2021 Nov 15, 2021	BUY	$20.88 - $56.08 $3.89 Million - $10.4 Million	186,091 New	186,091 $7.86 Million

Others Institutions Holding ADGI

# of Institutions

Shares Held

63.9M

Call Options Held

2.3K

Put Options Held

2.1K

View Full List

About Adagio Therapeutics, Inc.

Ticker ADGI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 108,831,000
Market Cap $505M
Description
Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company's lead product candidate is the ADG20 (adintrevimab), a neutralizing antibody that is in Phase 3 clinical trials for the treatmen...

More about ADGI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account

Northern Trust Corp Adagio Therapeutics, Inc. Transaction History